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ABSTRACT: Although tyrosine kinase inhibitors (TKIs) have revolutionized
cancer therapy in the past two decades, severe drawbacks such as strong adverse
effects and drug resistance limit their clinical application. Prodrugs represent a
valuable approach to overcoming these disadvantages by administration of an
inactive drug with tumor-specific activation. We have recently shown that hypoxic
prodrug activation is a promising strategy for a cobalt(III) complex bearing a TKI
of the epidermal growth factor receptor (EGFR). The aim of this study was the
optimization of the physicochemical properties and enhancement of the stability
of this compound class. Therefore, we synthesized a series of novel derivatives to
investigate the influence of the electron-donating properties of methyl
substituents at the metal-chelating moiety of the EGFR inhibitor and/or the
ancillary acetylacetonate (acac) ligand. To understand the effect of the different
methylations on the redox properties, the newly synthesized complexes were
analyzed by cyclic voltammetry and their behavior was studied in the presence of natural low-molecular weight reducing agents.
Furthermore, it was proven that reduction to cobalt(II) resulted in a lower stability of the complexes and subsequent release of the
coordinated TKI ligand. Moreover, the stability of the cobalt(III) prodrugs was investigated in blood serum as well as in cell culture
by diverse cell and molecular biological methods. These analyses revealed that the complexes bearing the methylated acac ligand are
characterized by distinctly enhanced stability. Finally, the cytotoxic activity of all new compounds was tested in cell culture under
normoxic and various hypoxic conditions, and their prodrug nature could be correlated convincingly with the stability data. In
summary, the performed chemical modifications resulted in new cobalt(III) prodrugs with strongly improved stabilities together
with retained hypoxia-activatable properties.
■ INTRODUCTION
The epidermal growth factor receptor (EGFR) belongs to the
family of receptor tyrosine kinases, a group of proteins that are
responsible for numerous signal transduction processes in the
human body (e.g., cell growth, differentiation, and metabo-
lism).1 Hence, an overexpression of the EGFR can be observed
in various types of solid tumors, including those of lung, head
and neck, ovary, breast, and colon.2,3 Especially in non-small-cell
lung cancer (NSCLC), which is still one of the leading causes of
cancer-related deaths worldwide, the EGFR is overexpressed in
at least 50% of the patients.4 Moreover, “activating mutations” of
the EGFR protein have been observed in ≤20% of the patients,
which results in a permanent activation of this signaling
pathway.5 As such, cancer cells are highly dependent on the
respective growth signals and the development of EGFR
inhibitors as targeted therapeutics has been of great interest
over the past two decades. As a result of this intensive research,
several small-molecule or antibody inhibitors targeting the
EGFR have been clinically developed mainly for NSCLC
treatment.6 The mode of action of low-molecular weight EGFR
tyrosine kinase inhibitors (TKIs) is the (ir)reversible binding
into the ATP-binding pocket, which hampers the activation of
the downstream signaling [e.g., phosphorylation of extracellular
signal-regulated kinases (ERKs)].7 The clinically approved
EGFR TKIs comprise gefitinib (Iressa, 2003), erlotinib
(Tarceva, 2004), afatinib (Gilotrif, 2013), and osimertinib
(Tagrisso, 2017), which are all used for the treatment of
NSCLC.6 In addition, erlotinib (in combination with
gemcitabine) is approved for advanced and metastatic
pancreatic cancer.8
Unfortunately, besides the rapid development of drug
resistance, EGFR- targeting TKIs in clinical application found
their limitations in insufficient tumor accumulation and
induction of side effects such as severe papulopustular skin
rashes, gastrointestinal-related adverse events, or fatigue.9 It is
noteworthy that the intensity of these observed “on-target”
adverse effects directly correlates with therapy response.10,11
Thus, patients suffering from the most severe side effects (and
consequently most likely to have to discontinue therapy) are the
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ones who would benefit most from EGFR inhibitor treatment.10
Because adverse effects usually arise from a lack of tumor
specificity, the use of prodrug systems is a promising approach to
overcoming these drawbacks. Anticancer prodrugs are defined
as inactivated (nontoxic) derivatives of drugs, which ideally
release their active moiety at the desired site of action (e.g.,
tumors) by specific activation.12 Cancer tissue distinguishes
itself from the healthy surroundings in different ways.13 One
well-researched example is the occurrence of hypoxic areas in
solid tumors caused by insufficient blood supply based on their
uncontrolled and fast growth.14,15 To exploit these tumor
characteristics, several substance classes of hypoxia-activated
prodrugs such as nitroaromatics, quinones, transition metal
complexes [especially cobalt(III) systems], and aromatic N-
oxides have been developed. Some of these compounds [e.g.,
tirapazamine, TH-302 (evofosfamide), and apaziquone] have
already been investigated even in clinical phase III studies;
however, no representative has reached clinical approval so far.16
Notably, for the large class of existing TKIs, only a few attempts
have been made to convert them into prodrugs that can be
activated under hypoxic conditions.17−20
With regard to metal-based drugs, cobalt complexes can be
used as attractive prodrug systems due to their adjustable redox
potential and well-established coordination chemistry.21−23
Most important for this prodrug system is the kinetic inertness
of octahedral cobalt(III) complexes, whereas (after a one-
electron reduction) the cobalt(II) state is labile with fast ligand
exchange processes.21,24 Applying this mechanism to the
hypoxic environment of a tumor, the inactive prodrug will
undergo an irreversible reduction in the hypoxic tissue with
Figure 1. Proposed mechanism of the hypoxia-activated cobalt(III) prodrug system. In healthy tissue (left), the cobalt(III) complex is too bulky to fit
into the ATP-binding pocket of the EGFR and is therefore biologically inactive. In the hypoxic environment of the tumor (right) an irreversible
reduction takes place. This results in the release of the TKI ligand with formation of cobalt(II) species {[Co(H2O)6]
2+ and mixed acac/H2O
complexes} and subsequent inhibition of EGFR-downstream signaling.
Scheme 1. Chemical Structures of EGFR Inhibitor Ligands L and MeL as well as Cobalt(III) Complexes Co(acac)2L
+,
Co(Meacac)2L
+, Co(acac)2MeL
+, and Co(Meacac)2MeL
+
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subsequent ligand release. In contrast, in healthy tissues the
complex is stable, preventing the ligand from exerting its
biological activity. It is noteworthy that Ware et al. already
showed that in the case of monodentate aziridine ligands, the
cobalt(II) complexes do not have sufficient stability under
normoxic conditions. Consequently, bidentate chelating ligands
are preferred for the design of novel prodrug complexes.21 We
have recently successfully developed the first cobalt(III)-based
prodrug [Co(acac)2L
+] for a new EGFR inhibitor (denoted as
L)17 (Figure 1). Notably, the potential of this new compound
class could be observed in several cancer cell models in vitro and
demonstrated encouraging results in vivo using xenograft tumor
models in mice. However, subsequent investigations showed
only moderate stability of the complex toward reduction in
blood serum. Consequently, the aim of this study was to further
improve this substance class by decreasing the cobalt redox
potential leading to higher stability. Therefore, we synthesized
several novel derivatives, evaluated their properties (electro-
chemical potential, interaction with natural reducing agents, and
serum stability), and correlated them with their cytotoxic
activity against cancer cell lines.
■ RESULTS AND DISCUSSION
Synthesis and Characterization. To design an EGFR
inhibitor that can coordinate to cobalt(III), we used in our
previous study the typical quinazoline ring of most approved
EGFR inhibitors but modified the 6 position by introducing an
ethylenediamine (“en”) type metal-binding moiety [L
(Scheme 1)].17 Reaction with Na[Co(acac)2(NO2)2] (acac =
acetylacetonate) yielded the cobalt(III) EGFR inhibitor ternary
complex Co(acac)2L
+. To develop derivatives with lower redox
potentials and consequently higher expected (blood plasma)
stabilities, we followed two strategies: (1) introduction of an
electron-donating methyl group at the “en”moiety (MeL) and/
or (2) using methylacetylacetone (Meacac) instead of acac as
the ancillary ligand.
MeL was synthesized using N-(3-bromophenyl)quinazoline-
4,6-diamine, N-Boc-(methylamino)-acetaldehyde, and sodium
cyanoborohydride. After deprotection with HCl,MeL could be
obtained in ∼80% yield as a dihydrochloride salt. The
cobalt(III) complexes were synthesized by reaction of Na[Co-
(acac)2(NO2)2] or Na[Co(Meacac)2(NO2)2] with L orMeL in
a water/methanol mixture in the presence of activated charcoal
following a procedure described by Denny et al.21 (Scheme 1).
Finally, addition of brine to the reaction mixture resulted in the
precipitation of the complex as a chloride salt. Afterward, the
crude product was purified by reversed-phase high-performance
liquid chromatography (HPLC) (without addition of acids to
the eluent to avoid a counter ion exchange). The novel
compounds were characterized by mass spectrometry, 1H and
13C one- and two-dimensional nuclear magnetic resonance
(NMR) spectroscopy, and elemental analysis.
Of note are especially the NMR spectra of the cobalt(III)
complexes. In the case of Co(acac)2L
+17 and Co(Meacac)2L
+,
two independent signal sets can be observed, belonging to two
pairs of diastereomers (Figure S1 and ref 17). The two
stereogenic centers originate from the propeller chirality of the
complex itself and the anilinic NH group. In the case of
methylated ligand MeL, an additional stereocenter is
formed,25,26 resulting in four sets of signals for complexes
Co(acac)2MeL
+ and Co(Meacac)2MeL
+ (Figures S2 and S3).
The presence of these isomers can be easily seen in the 1HNMR
spectra, where depending on the complex, two or four separated
singlets of the NH group appear (Figure S4). However,
especially in the aromatic area and within the “en” bridge the
protons tend to overlap. Therefore, an exact assignment of all
NMR signals could not be achieved (see Experimental Section).
Isolation of pure diastereomers by reversed-phase HPLC was
not possible, because the product peaks could not be separated
(also a change in the gradient or solvent and the addition of
formic acid did not result in sufficient separation).
Fluorescence Properties. In our previous work,17 we
showed that EGFR inhibitor ligand L possesses distinct
fluorescence properties with an emission maximum at 455 nm
upon irradiation at 370 nm. This fluorescence is completely
quenched by coordination to the cobalt(III) ion [Co(acac)2L
+].
Therefore, we also examined the fluorescence of MeL and the
novel complexes in phosphate-buffered saline (PBS) at pH 7.40.
The three-dimensional (3D) spectrum of MeL (Figure 2A) is
similar in intensity and maxima (λem = 455 nm, and λex = 365
nm) compared to L. In agreement to our previous data, the
fluorescence of all cobalt(III) complexes is negligible, most
probably due to the metal center, resulting in extremely fast
intersystem crossing rates in the excited state27 [Figure 2B for
Figure 2. (A) 3D full excitation−emission landscape of MeL (Rayleigh scattering of first and second order appears as diagonal ridges). (B)
Fluorescence emission spectra at a λex of 365 nm of MeL, Co(acac)2MeL
+, and Co(Meacac)2MeL
+ (the peaks at 420 nm are caused by Raman
scattering28). All measurements were performed in PBS at pH 7.40 (30 μM ligand, 30 μM complex, and 25.0 °C).
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Co(acac)2MeL
+ and Co(Meacac)2MeL
+]. Therefore, we could
exploit the fluorescence properties for stability studies of the
complexes.
Lipophilicity. The first physicochemical property we
investigated was the lipophilicity of the complexes, because it
is a critical parameter for passing biological membranes.
Distribution coefficients (D7.4) presented in Table 1 were
determined by the traditional shake-flask method in an
n-octanol/buffered aqueous solution at physiological pH. All
compounds containing an EGFR inhibitor ligand (L or MeL)
show highly lipophilic character, despite the positive charge of
the complexes. As expected, the methylated compounds are
more lipophilic than Co(acac)2L
+ (Table 1). However, all
complexes still show good water solubility. The active EGFR
inhibitor ligand L itself proved to be highly lipophilic (logD7.40 =
1.86).29 Therefore, the lipophilic character of the complexes is
mainly based on the coordinating EGFR inhibitor ligand and
just slightly modulated by the attachment of the cobalt-
(methyl)acetylacetonato fragment [the simple model complex
Co(acac)2en
+ is very hydrophilic with a log D7.40 value of
−1.86]. The highly lipophilic character of the complexes
apparently contradicts the relatively good water solubility
(0.5−1.0 mM in water or PBS). Variation of the composition
of the aqueous phase in the case of Co(acac)2L
+ revealed a
strong dependence of the distribution coefficient on the ion
content of the aqueous solution (see footnote of Table 1). This
phenomenon refers to ion pair formation taking place between
the single positively charged complex and anions like Cl− and
H2PO4
− present in the buffer system. Distribution coefficients
determined in 20 mM phosphate and 0.1 M KCl probably
represent best the lipophilicity of the complexes under
physiological conditions.
These results are in line with HPLCmeasurements, where the
retention time of the complexes increases with the number of
methyl substituents resulting in the following order: Co-
(acac)2L
+ < Co(acac)2MeL
+ < Co(Meacac)2L
+ <
Co(Meacac)2MeL
+.
Cyclic Voltammetry. As the reduction process is crucial for
the activation of cobalt(III)-based prodrug systems, the redox
properties of the complexes were investigated to elucidate the
effects of ligand methylation at different positions. Cyclic
voltammetry measurements were performed in aqueous
solution at pH 7.40 (10 mM phosphate buffer with 0.1 M
KCl). The voltammograms at a scan speed of 30 mV/s showed a
single irreversible cathodic peak in the range of 4−120 mV
versus the normal hydrogen electrode (NHE), which can be
assigned to the reduction of cobalt(III) to cobalt(II) (Figure 3).
Also, at a much higher scan speed of 1000 mV/s, the redox
processes were still completely irreversible (Figure S5).
Compared to reference compound Co(acac)2L
+ with a
cathodic peak at 62 mV versus NHE, the methylation of the
acac ligand Co(Meacac)2L
+ resulted in the desired lower
cathodic peak potential at 4 mV versus NHE. This trend is also
in agreement with literature data of cobalt(III) prodrug systems
containing nitrogen mustard ligands.21 In contrast to the
expectations, methylation of the “en” moiety of the EGFR
inhibitor ligandCo(Meacac)2MeL
+ did not further decrease the
reduction potential but resulted in a slightly higher cathodic
potential (17 mV vs NHE). Analogously, Co(acac)2MeL
+ also
showed an increased potential (120 mV vs NHE) compared to
that of Co(acac)2L
+ (62 mV vs NHE).
Notably, the reduction potential of reference compound
Co(acac)2en
+ was distinctly lower with a value of −141 mV
versus NHE even compared to the most promising representa-
tive of the EGFR inhibitor-containing complexes, Co-
(Meacac)2L
+, at 4 mV versus NHE. To verify that the adjacent
aromatic moiety of the quinazoline is responsible for this shift
and that methylation of the “en” moiety indeed increases the
redox potential, additional model complexes were synthesized
(Figure 4): (1) Co(acac)2PhEn
+ to determine the influence of
the phenyl moiety and (2)Co(Meacac)2en
+,Co(acac)2MeEn
+,
and Co(Meacac)2MeEn
+ to confirm the shifts of the cathodic
peak potential as a result of the different methylations (MeEn =
N-methylethylenediamine; PhEn = N-phenylethylenediamine).
The synthesis of the complexes followed a similar procedure as
described above, and the only difference was the use of
ammonium hexafluorophosphate for precipitation of the
complexes (see details in the Experimental Section).
Indeed, cyclic voltammetric measurements performed for
Co(acac)2PhEn
+ showed a strong shift of the cathodic peak
potential to 49 mV in comparison to that of Co(acac)2en
+ at
−141 mV (Figure 4). This can be explained by the electron-
withdrawing effect of the phenyl ring, which distinctly increases
the redox potential of the cobalt center. With regard to the
methylations at the “en” versus the acac moiety, the model
complexes confirmed (even more pronounced) the tendencies
observed for the EGFR inhibitor-containing complexes [except
Co(acac)2MeEn
+ with a slightly lower Ec value]. The
introduction of the methylated acac moiety led to a significantly
Table 1. Distribution Coefficients (D7.40) of the Complexes at
pH 7.40 [T = 25.0 °C, and I = 0.1 M (KCl)]
complex log D7.40
Co(acac)2L
+a 1.59 ± 0.06
Co(Meacac)2L
+ 2.24 ± 0.04
Co(acac)2MeL
+ 2.05 ± 0.17
Co(Meacac)2MeL
+ >2.7
Co(acac)2en
+ −1.86 ± 0.05
L 1.86 ± 0.0329
aDistribution coefficients measured under different conditions: log D
= −0.55 ± 0.01 (water, pH ∼6.5), −0.09 ± 0.03 [20 mM phosphate
buffer (pH 7.40)], and 2.22 ± 0.03 [20 mM phosphate buffer and
0.58 M KCl (pH 7.40)].
Figure 3. Cyclic voltammograms of Co(acac)2L
+, Co(Meacac)2L
+,
Co(acac)2MeL
+, and Co(Meacac)2MeL
+ in 10 mM phosphate buffer
(pH 7.40) (1.5mMcomplex, I = 0.10MKCl, scan rate of 30mV/s, 25.0
°C). Potentials are referenced to the NHE.
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decreased reduction potential, whereas the methylation of the
“en” ligand showed the opposite effect. Therefore, in the case of
Co(Meacac)2MeEn
+, the influence of the methylated acac
moiety is widely annihilated by the methylation of “en”.
Notably, all reduction processes were completely irreversible
independent of the scan speed (30−1000 mV/s). In the
literature, the proposed mechanism for cobalt(III) prodrugs
usually comprises that in healthy tissues, which are provided
with a sufficient supply of oxygen, and after the reduction to
cobalt(II), an immediate re-oxidation step occurs, regenerating
the inert cobalt(III) complex.23,30 However, at the same time for
most of the cobalt(III) complexes in the literature, the redox
process in an aqueous solution is completely irreversible.31−34
This is in line with pulse radiolysis studies also revealing that the
re-oxidation rates under normoxic conditions are too slow.35
Instead, competition between oxygen and the cobalt(III)
complexes for one-electron reductants was suggested. Interest-
ingly, despite this irreversibility, e.g., cobalt(III) nitrogen
mustard complexes showed promising hypoxia selective
anticancer activity.32 In particular, Ware et al. tried to optimize
the electrochemical properties of cobalt(III) prodrug systems,
resulting in (partially) reversible complexes with highly hypoxia
selective activity against cancer cells.36 Unfortunately, their lead
compound did not show significant activity in a mouse model.
However, as our compound class, which displays irreversible
electrochemical properties, also possesses hypoxia-dependent
anticancer activity in a mouse model,17 this indicates that the
irreversibility of the reduction process does not interfere with
the in vivo effectiveness. Therefore, it is currently unknown how
the exact mechanism of the hypoxic selectivity of cobalt(III)
complexes works and which electrochemical properties are ideal.
Aqueous Solution Stability of the Formed Cobalt(II)
Complexes. After reductive activation of the cobalt(III)
prodrugs, it is essential to investigate whether the formed
cobalt(II) complexes indeed can release the coordinated
targeting ligand. For this reason, we selected two ternary
Figure 4.Cobalt(III) model complexes synthesized to investigate the effect of the methyl and phenyl substitution at the “en” and/or acac moiety. Ec is
the cathodic peak potential vs NHE of the cobalt complexes measured at a scan rate of 30 mV/s in 10 mM phosphate buffer (pH 7.4).
Table 2. Proton Dissociation Constants (Ka) of Hacac as well as Fully Protonated MeEn and PhEn Together with the Overall
Stability Constants (β) for the Binary and Ternary Cobalt(II) Complexes Determined by pH-Potentiometric Measurementsa
acac (A) MeEn (B) PhEn (B)
pKa1 8.80 ± 0.01
b pKa1 7.04 ± 0.02 1.85 ± 0.01
c
pKa2 − pKa2 9.98 ± 0.01 9.34 ± 0.01c
Log β Values of the Binary Complexesc
[Co(II)L]+ 5.05 ± 0.02b [Co(II)L]2+ 5.26 ± 0.01 3.63 ± 0.05
[Co(II)L2]
0 8.66 ± 0.05b [Co(II)L2]
2+ 9.15 ± 0.02 6.75 ± 0.09
[Co(II)L3]
− − [Co(II)L3]2+ 12.94 ± 0.04 −
Log β Values of the Ternary Complexes
[Co(II)AB]+ 9.82 ± 0.05 8.03 ± 0.15
[Co(II)A2B]
0 12.73 ± 0.09 12.08 ± 0.09
[Co(II)AB2]
+ 13.20 ± 0.12 11.29 ± 0.13
aIn ternary (mixed-ligand) complexes, “A” denotes acac and “B” denotes MeEn or PhEn [25.0 °C; I = 0.1 M (KCl)]. bReported data for the
cobalt(II) acac system: pKa1 = 8.83, log β[CoL] = 5.10, and log β[CoL2] = 9.08 (25 °C; I = 0.1 M NaClO4).
40 cpKa values of 1.76 ± 0.03 and 9.42
± 0.03, and 1.73 ± 0.03 and 9.37 ± 0.03, determined by ultraviolet−visible and spectrofluorometric titrations, respectively.
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systems as models to study the potential liberation of the (N,N)
ligand from the mixed-ligand cobalt complex upon reduction.
Thus, the aqueous stability of several cobalt(II) complexes was
investigated under strictly anaerobic conditions. Due to the
limited water solubility of cobalt(II) chloride complexes with L,
model ligands with better solubility, namely, MeEn and PhEn,
were used. First, deprotonation processes of the acetlyacetone
(Hacac) and the fully protonated MeEn and PhEn ligands were
followed at pH 2.0−11.5 (Table 2). The calculated pKa for
Hacac of 8.80 is in good agreement with literature data (pKa =
8.82) reported at I = 0.1 M NaClO4.
37 The two pKa values of
MeEn [pKa1 = 7.04 (MeNH2
+); pKa2 = 9.98 (NH3
+)]
correspond well to the deprotonation constants of the fully
protonated form of “en”,38,39 but the pKa1 dramatically differs
from that of PhEnH2
2+ (pKa1 = 1.85; pKa2 = 9.34). The latter
model ligand is quite comparable to EGFR inhibitor L (pKa1 <
1.0; pKa2 = 9.21) investigated in our previous work.
29
Following the determination of the stability constants for the
binary complexes (Table 2), overall stability constants for the
mixed-ligand complexes formed in the cobalt(II)−acac−MeEn
and cobalt(II)−acac−PhEn ternary systems were calculated on
the basis of pH-potentiometric titrations. Three types of
complexes were formed, [CoAB]+, [CoA2B], and [CoAB2]
+,
where “A” denotes acac and “B” refers to MeEn or PhEn.
Concentration distribution curves in Figure 5 were computed
using the stability constants of the 1:2:1 cobalt(II)−acac−PhEn
composition that corresponds to the reduced form of Co(II)-
(acac)2L
0. On the basis of these data, negligible amounts (<1%)
of PhEn are coordinated to cobalt(II) at pH 7.4. For the 1:2:1
cobalt(II)−acac−MeEn system, ∼11% are still coordinated to
cobalt(II) at pH 7.4 (Figure S6). However, it has to be
mentioned that these calculations were performed for 1 mM
cobalt(II) (where the titrations were performed), and the
amount of the intact ternary complex further decreases with
lower concentrations [e.g., in the latter system at pH 7.4 and 0.1
mM cobalt(II), the coordinated MeEn fraction is only ∼2%].
As a conclusion, these measurements strongly support the
assumption that after reduction of the cobalt(III) complexes, the
respective EGFR-targeting ligand completely dissociates, which
enables subsequent inhibition of the EGFR-downstream
signaling.
Interaction with Natural Low-Molecular Weight
Reducing Agents. Next, we investigated if common bio-
logically relevant low-molecular weight reducing agents can
reduce Co(acac)2L
+ or Co(Meacac)2L
+. Glutathione (GSH)
and reduced nicotinamide adenine dinucleotide (phosphate)
(NADH/NADPH) are responsible for the redox equilibrium in
the cytosol, while ascorbic acid (AA) is found in both extra- and
intracellular space. Among them, NADH is the strongest
reducing agent (formal potential at pH 7.0 of −0.32 V for
NAD+/NADH41), followed by GSH (−0.24 V for GSSG/GSH
at pH 7.041). For AA, usually 0.06 V for dehydro-L-ascorbate/
AA at pH 7.0 is reported.42 However, recent literature also
suggests even higher values in the range of 0.35−0.50 V.43,44
GSH is produced in cells at concentrations (1−10 mM) at least
one order of magnitude higher than those of NADH (30−100
μM).45,46
The interaction of AA, GSH, and NADH at pH 7.40
(phosphate buffer) was investigated exemplarily for Co-
(acac)2L
+ and Co(Meacac)2L
+. The reaction was followed by
ultraviolet−visible (UV−vis) and fluorometric detection at 25
°C with a 10-fold excess of reducing agent. Spectrofluorometry
was proven to be an effective technique for monitoring this
redox reaction, because the free EGFR inhibitor ligand L is
highly fluorescent, while its cobalt(III) complex has negligible
emission (vide supra).17 Accordingly, an increase in the emission
intensity is expected upon reduction and concomitant release of
the free ligand. Figure 6 indicates practically no reduction
process of Co(Meacac)2L
+ in the presence of 10 equiv of GSH,
and no significant amount of free L appeared in samples even
after 24 h. The same tendency was observed by UV−vis
detection (data not shown). For Co(acac)2L
+, again no
liberation of the active ligand could be detected within 24 h.
AA and NADH were also not able to reduce the two complexes
even after 24 h. These data show that the complexes are highly
stable in aqueous solution and biologically relevant low-
molecular weight non-enzymatic reducing agents are not
responsible for the reduction of the cobalt(III) complexes. For
other hypoxia-activatable drugs like tirapazamine and its second-
generation analogue SN30000, P450 oxidoreductases (POR)
have been proposed as proteins responsible for reduction.47
However, Ware and co-workers36 and Wilson and co-workers48
showed for different types of cobalt(III) complexes that the
cytotoxicity did not change in cells overexpressing POR
Figure 5.Concentration distribution diagram for the 1:2:1 cobalt(II)−
acac−PhEn system. A = acac; B = PhEn [1 mM cobalt(II); I = 0.10 M
(KCl); 25.0 °C].
Figure 6. Fluorescence emission spectra of Co(Meacac)2L
+ in the
presence of 10 equiv of GSH followed for 24 h. The dashed spectrum
corresponds to the emission spectrum of free EGFR inhibitor L [ccomplex
= 15 μM; cfree ligand = 15 μM; λEX = 350 nm; pH 7.40 (10 mMphosphate
buffer and 0.1 M KCl); 25.0 °C].
Inorganic Chemistry pubs.acs.org/IC Article
https://dx.doi.org/10.1021/acs.inorgchem.0c03083
Inorg. Chem. 2020, 59, 17794−17810
17799
compared to the parental cell line. Therefore, the actual reducing
molecules or reductase(s) are still unknown.
Serum Stability. The data presented in the previous
sections indicate that even in the presence of low-molecular
weight reducing agents the cobalt(III) complexes are completely
stable. Therefore, we wanted to investigate if this is still true in a
more elaborate biological environment like blood serum. To this
end, the four EGFR inhibitor complexes were dissolved in 50
mM phosphate puffer and mixed in a 1:10 ratio with fetal calf
serum (FCS; buffered with 150 mM phosphate buffer to keep a
stable pH of 7.4) to a final concentration of 50 μM. The samples
were incubated at 37 °C and after 0, 2, 6, 24, and 26 h extracted
with acetonitrile and measured by HPLC-MS. The extracted ion
mass chromatogram of Co(acac)2L
+ clearly showed the time-
dependent release of the free EGFR inhibitor (Figure 7A; red
peak at 11.8 min, m/z 358.1). The intact complex could be
observed at 14.2 min (blue peak, m/z 614.0). The red signal at
the same retention time (Figure 7A; 14.2 min, m/z 358.1) is a
mass spectrometry artifact and belongs to the free ligand
generated during ionization of the complex. In contrast, themass
spectra of Co(Meacac)2L
+ incubated in serum revealed much
smaller amounts of the released ligand (Figure 7B).
The same trend was observed for Co(acac)2MeL
+ and
Co(Meacac)2MeL
+ (Figure S7). Therefore, in this experiment,
a distinct increase in the stability in the presence of the Meacac
ligand could be observed in both complexes with ∼85% intact
compound after serum incubation for 26 h at 37 °C. The
stability of these complexes was much higher than that of
Co(acac)2L
+ and Co(acac)2MeL
+, having only 43% and 50%
intact compound after 26 h, respectively (Figure 8). In general,
these results are in accordance with the cyclic voltammetry
measurements, where Co(Meacac)2L
+ and Co(Meacac)2MeL
+
showed the lowest redox potential of the four complexes.
Together, this indicates a strong influence of the methylation of
acac for the stability of cobalt(III) prodrugs; however, no
beneficial effect was seen in the case of methylation of the “en”
moiety.
Biological Investigations. Evaluation of the Complex
Stability in the Presence of Cells under Normoxic Conditions.
As a next step, we addressed the question of whether the new
derivatives are also more stable than Co(acac)2L
+ in the
presence of cells under normoxic cell culture conditions
(medium containing 10% serum at 37 °C, 21% O2, and 5%
CO2). Therefore, the stability of the cobalt(III) complexes was
monitored indirectly by microscopy as well as flow cytometry in
A431 cells by exploiting the fluorescence of released ligands L
andMeL. As shown in Figure 9, the stability of the compounds
bearing a Meacac ligand was distinctly increased compared to
those of the acac derivatives. Consequently, while in case of the
acac drugs most of the ligand was already released after 24 h
(clearly visible by the blue fluorescence of the cells), the
micrographs of the Meacac compounds remained widely
unchanged.
This also could be confirmed by subsequently performed flow
cytometry investigations (Figure 10). In detail, the evaluation of
the fluorescence intensities showed that the cobalt complexation
led to a 1.9−2.6-fold reduced mean fluorescence and a 4−90-
Figure 7. Time-dependent stability of (A)Co(acac)2L
+ and (B)Co(Meacac)2L
+ incubated in FCS at 37 °C (pH 7.4, 150 mM phosphate buffer) and
analyzed by HPLC−mass spectrometry (depicted are the extracted ion mass chromatograms). Due to the different ionization properties, the
intensities of the free ligand (m/z 358.1) and cobalt(III) complexes (m/z 614.0 or 642.1) cannot be directly compared.
Figure 8. Stability measurements of Co(acac)2L
+, Co(Meacac)2L
+,
Co(acac)2MeL
+, and Co(Meacac)2MeL
+ incubated in FCS at 37 °C
(pH 7.4, 150 mM phosphate buffer) and analyzed by mass
spectrometry over a period of 26 h. The y-axis shows the relative
ratio of the integrated peak areas of the intact complex over time (in
percent) compared to the area at the starting point (0 h).
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fold reduced number of ligand-positive cells at the 6 h time
point. This is in good agreement with the already published data
on Co(acac)2L
+.17 However, after incubation for 24 h 100% of
cells treated with the two acac complexes became ligand-
positive, resulting in a mean fluorescence similar to that of the
samples treated with the free ligand. In contrast, in the samples
of the Meacac-containing group, the mean fluorescence was
much less affected, as the percentage of ligand-positive cells
increased only from 2.2% to 18.4% and from 1% to 7.5%, in the
cases of Co(Meacac)2L
+ and Co(Meacac)2MeL
+, respectively.
This indicates that in contrast to the acac-auxiliary ligand, the
cobalt(III) complexes bearing a Meacac moiety are highly stable
under normoxic cell culture conditions for more than 1 day.
To evaluate if cobalt complexation also prevents EGFR
inhibition under normoxic conditions, Western blot analyses of
the EGFR phosphorylation at position Y1068 (activating
phosphorylation) as well as the activation of the EGFR
downstream protein ERK 1/2 were performed. To ensure an
EGFR-dependent signaling, A431 cells were serum-starved for
24 h, incubated with the indicated cobalt(III) drugs at three
different concentrations for 2 h, and stimulated by EGF for
10 min prior to protein isolation (Figure 11). In agreement with
our stability data, the Meacac ligand set efficiently prevented the
release of both L andMeL, indicated by the distinctly weakened
EGFR-inhibitory potential of Co(Meacac)2L
+ and Co-
(Meacac)2MeL
+ in comparison to Co(acac)2L
+ and Co-
(acac)2MeL
+. The potent EGFR inhibition by free MeL and L
under these conditions is shown in Figure S8 and ref 17,
respectively.
Hypoxia-Dependent Cytotoxicity of the Cobalt Complexes.
Finally, we wanted to evaluate whether theMeacac coordination
sphere also affects the hypoxic activation of the complexes. To
characterize the activity of the free EGFR inhibitor ligands, prior
to the assessment of their anticancer activity in cell culture, the
EGFR-inhibitory potential was investigated in a cell-free kinase
inhibition assays in the presence of a 10-fold excess of ATP. The
results showed that the methylation at the terminal amino group
slightly reduced the EGFR inhibition potential from an IC50
value of 0.29 nM for L to a value of 0.41 nM for MeL (Figure
S9).
Subsequently, MTT-based cytotoxicity assays of the com-
plexes in comparison to the respective metal-free ligands were
performed under different O2 levels (21%, 5%, 1%, or 0.1%)
(Table 3 and Figure 12). As expected, the two EGFR inhibitor
ligands L and MeL did not show distinct differences in their
anticancer activity in normoxic versus the different hypoxic
conditions. However,MeL was approximately twice as effective
as L. This is interesting, as the kinase assay mentioned above did
Figure 9. Fluorescence microscopic measurements indicating the release of the ligand from the different cobalt(III) complexes. Release of (A) L and
(B) MeL from the different cobalt(III) complexes under normoxic cell culture conditions (37 °C, 21% O2, and 5% CO2) using UV fluorescence
microscopy. A431 cells were incubated with 10 μMdrugs for 6 or 24 h. Images are overlays of representative fluorescence and differential interference
contrast microscopies (10× objective) of the different treatments processed by ImageJ software.
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Figure 10. Release of (A) L or (B) MeL from the indicated cobalt(III) complexes under normoxic cell culture conditions (37 °C, 21% O2, and 5%
CO2) by flow cytometry. A431 cells were incubated with 10 μM drugs for 6 or 24 h, and the fold change in fluorescence intensity (left, after
normalization with fluorescence intensity of the cells) and the percent of fluorescence-positive cells (right) were evaluated using Diva Software and
GraphPad Prism. Statistical significance was calculated via two-way analysis of variance with amultiple-comparison test and Bonferroni correction with
p < 0.001 (***).
Figure 11. Impact of new cobalt(III) complexes on the EGFR signaling cascade (pEGFR, pERK 1/2) under normoxic conditions. A431 cells were
grown in medium with or without FCS and treated with the indicated drug for 2 h. After EGFR stimulation with 50 ng/mL EGF for 10 min, cells were
harvested, lysated, and further analyzed byWestern blotting. The ratios of pEGFR or pERK 1/2 levels of the treated samples (after normalization to the
loading control β-actin) to the levels of the control (−FCS and +EGF) are given below the respective bands.
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not show a higher EGFR inhibitor potency for this new
inhibitor, probably indicating a shift in the target kinase
spectrum.
In good agreement with our previous study,17 the formerly
investigated Co(acac)2L
+ exhibited an ∼2-fold weaker anti-
cancer activity under normoxia (Table 3) than under reduced
oxygen conditions (≤1%). Also in the case of Co(acac)2MeL+,
the cobalt complex was ∼2-fold less active than the respective
free ligand. However, under hypoxic conditions, Co-
(acac)2MeL
+ did not show full MeL activity even under the
lowest oxygen levels of 0.1%. In contrast, the two Meacac-
containing cobalt(III) complexes both showed IC50 values of
>50 μM under normoxic conditions and also weak hypoxia with
5% O2 did not enhance the activity to a relevant extent.
However, the reduction of oxygen levels to 1% significantly (p <
0.001) increased the cytotoxic activity of the two prodrugs,
resulting in IC50 values of∼25 and∼32 μM forCo(Meacac)2L+
and Co(Meacac)2MeL
+, respectively. In the case of Co-
(Meacac)2L
+, a further decrease in the O2 levels from 1% to
0.1% generated similar results. In contrast, for Co-
(Meacac)2MeL
+, the presence of 0.1%O2 induced an additional
significant (p < 0.05) improvement in drug efficacy (IC50 value
of ∼20 μM) compared to that for 1% O2 hypoxia, resulting in a
2.9-fold increase in cytotoxicity compared to that under
normoxic conditions.
It is well-known that cobalt(II) ions have some biological
effects like an upregulation of the expression of the hypoxia
inducible factor (HIF).49 Furthermore, a possible effect could
also arise from iron(III) binding of releasedMeacac.50 However,
we already investigated in our previous work17 CoCl2 as well as
the complexes [Co(II)(acac)2en] and [Co(III)(acac)2en]PF6
with a simple ethylenediamine ligand without an EGFR-binding
moiety. No significant cytotoxic activity could be observed
against A431 cells under both normoxia and hypoxia. Therefore,
we can widely exclude a contribution of Co(II) ions or released
acac (and subsequent iron chelation) on the anticancer activity
of EGFR inhibitor-bearing cobalt(III) prodrugs.
■ CONCLUSIONS
Despite the revolutionizing effect they have had on cancer
therapy, TKIs are limited in their clinical application due to
severe side effects and rapid development of drug resistance.
Hence, the design of tumor-specifically activated prodrugs is an
important strategy for reducing these adverse effects. We
Table 3. IC50 Values of L and MeL in Comparison to the Respective Cobalt(III) Prodrugs against A431 Cancer Cells after
Treatment for 72 h under Different O2 Levels (21% to 0.1%)
a
IC50 (μM ± SD)
drug normoxia hypoxia with 5% O2 hypoxia with 1% O2 hypoxia with 0.1% O2
L 12.0 ± 1.3 12.8 ± 0.9 12.7 ± 2.0 13.7 ± 2.9
MeL 6.9 ± 1.8 8.7 ± 1.2 5.5 ± 0.4 5.4 ± 0.8
Co(acac)2L
+ 22.9 ± 5.7b 18.7 ± 4.0b 13.4 ± 0.3 7.2 ± 1.4
Co(Meacac)2L
+ 51.9 ± 9.4c,e 45.5 ± 2.7c 25.3 ± 3.9 23.5 ± 5.1
Co(acac)2MeL
+ 15.1 ± 1.6 13.5 ± 3.2 12.5 ± 3.1 11.9 ± 3.5
Co(Meacac)2MeL
+ 58.6 ± 4.4c,e 55.2 ± 1.4c 32.0 ± 2.9d 19.9 ± 1.0
erlotinib 13.3 ± 4.7 nd 14.4 ± 4.0 nd
aValues are given as means ± SD of at least three independent experiments performed in triplicate. Statistical significance, between the drugs under
normoxic and different hypoxic conditions, was calculated via one-way analysis of variance with a multiple-comparison test and Bonferroni
correction. bp < 0.01 compared to hypoxia with 0.1% O2.
cp < 0.001 compared to hypoxia with 1% and 0.1% O2.
dp < 0.05 compared to hypoxia
with 0.1% O2.
ep < 0.001 compared to the corresponding ligand and Co(acac)2X
+ derivative under normoxia.
Figure 12.Cytotoxic activity of the indicated compounds against A431 cancer cells. The incubation time of the compounds on the cells was 72 h under
normoxic and three different hypoxic conditions (5%, 1%, or 0.1% O2). Values are given as means ± the standard deviation of one representative
experiment performed in triplicate.
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recently established a hypoxia-activatable cobalt(III) prodrug
bearing an EGFR inhibitor ligand [Co(acac)2L
+], which showed
promising results in vitro as well as in vivo.17 The aim of this
study was to further improve the stability of this type of prodrug
by introducing electron-donating methyl groups to lower the
reduction potential. Methylation was performed at the chelating
moiety of the EGFR inhibitor and/or the acac ancillary ligand.
Interestingly, methylation of the EGFR inhibitor ligand
[Co(acac)2MeL
+] alone did not result in the expected lower
cobalt(III) reduction potential. However, this aim was reached
using Meacac as the ancillary ligand, and complexes Co-
(Meacac)2L
+ and Co(Meacac)2MeL
+ showed highly increased
stability in blood plasma. This stability trend could also be
confirmed in cell culture using fluorescencemicroscopy and flow
cytometry, exploiting the quenched fluorescence of the EGFR
inhibitor ligand when coordinated to cobalt(III). Evaluation of
the cytotoxic activity of all compounds under normoxia versus
hypoxia revealed that the complexes with distinctly higher
stability still possess promising hypoxia-activatable properties.
However, the IC50 values at 0.1%O2 after 72 h were significantly
higher compared to those of the free EGFR inhibitor ligands.
More in-depth studies are now needed to evaluate the
underlying reasons for this effect. Finally, a balance between
sufficient stability of the complex and tumor-specific release of
the EGFR inhibitor ligand is needed. However, only evaluation
in future in vivo experiments will reveal whether Co-
(Meacac)2MeL
+ is a promising candidate with both high
stability and activity.
■ EXPERIMENTAL SECTION
Materials and Methods. All solvents and reagents were obtained
from commercial suppliers. They were, unless stated otherwise, used
without further purification. Anhydrous MeOH and tetrahydrofuran
over molecular sieves were bought from Fisher Chemicals. The
precursors Na[Co(acac)2(NO2)2] andNa[Co(Meacac)2(NO2)2] were
obtained following the protocol of Denny et al.21 Co(acac)2en
+,
Co(acac)2L
+, and L were synthesized according to our previous
publication.17
For all HPLC measurements, Milli-Q water (18.2 MΩ cm, Merck
Milli-Q Advantage,Merck, Darmstadt, Germany) was used. Preparative
RP-HPLC was performed on an Agilent 1200 Series system controlled
by Chemstation software. As the stationary phase, either a XBridge
BEH C18 OBD Prep Column (130 Å, 5 μm, 19 mm × 250 mm) or an
Atlantis T3 OBD Prep Column (100 Å, 10 μm, 19 mm × 250 mm),
each from Waters Corp., was used. The general procedure included a
flow rate of 17.06 mL/min, an injection volume of ≤10 mL, and a
column temperature of 25 °C. Milli-Q water and acetonitrile (ACN)
without addition of acids were used as eluents unless stated otherwise.
Stability and kinetic experiments were analyzed on an Agilent 1260
Infinity system using aWaters Atlantis T3 column (150 mm× 4.6 mm)
coupled to a Bruker amaZon SL ESI mass spectrometer. If not stated
otherwise, water (containing 0.1% formic acid) and ACN (containing
0.1% formic acid) were used as eluents with a gradient of 1% to 99%
ACN within 29 min. Elemental analyses were performed by the
Microanalytical Laboratory of the University of Vienna on a Perkin
Elmer 2400 CHN Elemental Analyzer. Electrospray ionization (ESI)
mass spectra were recorded on a Bruker amaZon SL ion trap mass
spectrometer in positive and/or negative mode by direct infusion.
High-resolution mass spectra were recorded on a Bruker maXis UHR
ESI time-of-flight mass spectrometer. Expected and experimental
isotope distributions were compared. 1H and 13C NMR one- and two-
dimensional spectra were recorded in DMSO-d6 with a Bruker FT-
NMR AV NEO 500 MHz spectrometer at 500.10 (1H) and 125.75
(13C) MHz at 298 K or a Bruker FT-NMR AVIII 600 MHz
spectrometer at 600.25 MHz (1H) and 150.93 MHz (13C). Chemical
shifts (parts per million) were referenced internally to the solvent
residual peaks. For the description of the spin multiplicities the
following abbreviations were used: s, singlet; d, doublet; t, triplet; q,
quartet; m, multiplet. For the NMR description of the synthesized
compounds, the following abbreviations were used: acac, acetylacetone;
Meacac, methylacetylacetone; en, ethylenediamine; MeEn, N-methyl-
ethylenediamine; phEn, N-phenylethylenediamine; ph, phenyl; quin,
quinazoline.
Synthesis. tert-Butyl [2-({4-[(3-Bromophenyl)amino]quinazolin-
6-yl}amino)ethyl](methyl)carbamate. N-(3-Bromophenyl)-
quinazoline-4,6-diamine (1.5 g, 4.81 mmol) was dissolved in absolute
MeOH (47 mL) under an argon atmosphere. Freshly distilled acetic
acid (276 μL, 4.81 mmol) and molecular sieves (823 mg, 3−4 Å, dried
overnight at 150 °C) were added. N-Boc-(methylamino)-acetaldehyde
(1 g, 5.77 mmol) was dissolved in absolute MeOH (5 mL), and the
mixture was added dropwise to the yellow reaction solution. After the
mixture had been stirred for 1 h, sodium cyanoborohydride (363 mg,
5.77 equiv) was added in small portions and the reaction mixture was
allowed to stir overnight under an argon atmosphere. The next day the
solvent was removed, and the yellow residue was extracted in 600mL of
EtOAc and washed with 400 mL of 1 M HCl, saturated NaHCO3, and
brine. The organic phase was separated, dried over Na2SO4, and
concentrated in vacuo. The crude product was purified via flash
chromatography (15:1 dichloromethane/MeOH). Yield: 1.48 g (65%).
1HNMR (500.1MHz, DMSO-d6): δ 1.19 (s, 6H), 1.39 (s, 3H), 1.41 (s,
3H), 2.77−2.93 (m, 2H), 3.42−3.50 (m, 2H), 6.31 (d, J = 8.0 Hz, 1H),
7.91−7.31 (m, 3H), 7.35 (t, 1H), 7.56 (d, J = 2.0 Hz, 1H), 7.91 (d, J =
2.0 Hz, 1H), 8.17 (s, 1H), 8.39 (s, 1H), 9.34 (d, J = 6.0 Hz, 1H).
N4-(3-Bromophenyl)-N6-[2-(methylamino)ethyl]quinazoline-4,6-
diamine Dihydrochloride (MeL). To a solution of tert-butyl [2-({4-
[(3-bromophenyl)amino]quinazolin-6-yl}amino)ethyl](methyl)-
carbamate (1.48 g, 3.12 mmol) in EtOH (30 mL) was added
concentrated HCl (1.25 mL, 40.0 mmol), and the reaction mixture was
refluxed for 3 h. The solution was cooled to room temperature and
stored overnight at 4 °C. The yellow precipitate was filtered off, washed
with EtOH, and dried in vacuo. Yield: 1.11 g (80%). 1H NMR (600.25
MHz, DMSO-d6): δ 2.61 (t, 3H, H23), 3.15 (m, 2H, H21), 3.67 (m,
2H,H20), 7.19 (s, 1H,H18), 7.45 (t, 3H,H16), 7.48−7.54 (m, 2H,H2,
H15), 7.77 (d, 1H, J = 2.0 Hz, H3), 7.88 (d, 1H, J = 2.0 Hz, H11), 8.00
(s, 1H, H6), 8.13 (s, 1H, H13), 8.78 (s, 1H, H8), 9.09 (s, 2H, H22),
11.50 (s, 1H, H17). 13C NMR (150.93 MHz, DMSO-d6): δ 32.45
(C23), 38.93 (C21), 46.20 (C20), 98.57 (C6), 115.42 (C5), 120.73
(C3), 121.00 (C14), 123.71 (C11), 126.53 (C2), 127.23 (C13), 128.72
(C15), 130.41 (C16), 130.88 (C4), 138.67 (C12), 146.30 (C8), 148.57
(C1), 158.23 (C10). MS: calcd for [C17H18BrN5]
+, 372.08; found,
372.08. Anal. Calcd for C17H18BrN5·2HCl (Mr = 445.18 g/mol): C,
45.86; H, 4.53; N, 15.73. Found: C, 45.75; H, 4.22; N, 15.47.
Bis(3-methyl-2,4-pentanedionato) N6-(2-Aminoethyl)-N4-(3-
bromophenyl)quinazoline-4,6-diamine Cobalt(III) Chloride [Co-
(Meacac)2L
+]. Na[Co(Meacac)2(NO2)2] (84.4 mg, 0.22 mmol) was
dissolved in H2O (1.6 mL) and MeOH (4.5 mL). L (100 mg, 0.23
mmol) was dissolved in H2O (1 mL), neutralized with NaOH (1.65
mL, 0.28M inMeOH), and subsequently added to the cobalt precursor
solution together with activated charcoal (64 mg). The resulting
mixture was stirred for 1 h at room temperature, filtered through Celite,
and washed with small amounts of a MeOH/H2O mixture (1:1). Brine
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(30mL) was added to the filtrate, and the resulting solution was left at 4
°C overnight. The formed green precipitate was filtered off the next day.
The crude product (250 mg of a dark green solid) was purified by RP-
HPLC (Xbridge, H2O/MeOH, isocratic 57:43, without formic acid or
TFA to avoid counter ion exchange). Yield: 67 mg (44%). The ratio of
the two isomers was 1:0.36.
Shifts of the main isomer. 1H NMR (500.1 MHz, DMSO-d6): δ 1.00
(s, 3H, CH3, Meacac), 1.65 (s, 3H, CH3, Meacac), 1.88 (s, 3H, CH3,
Meacac), 2.05−2.06 (m, 6H, CH3, Meacac), 2.35 (s, 3H, CH3,
Meacac), 2.67−2.97 (m, 3H, CH2, en), 3.60−3.69 (m, 1H, CH2, en),
5.28−5.37 [m, 1H, CH, NH2(en)], 5.73−5.80 [m, 1H, CH, NH2(en)],
7.36−7.43 (m, 2H, ph), 7.52 (dd, 1H, J = 9 Hz, J = 2 Hz, quin), 7.67 (d,
1H, J = 9Hz, quin), 7.82−7.89 (m, 1H, ph), 7.93 [d, 1H,NH(en)], 8.10
(s, 1H, ph), 8.14−8.17 (m, 1H, quin), 8.65−8.70 (m, 1H, quin), 10.12
(s, 1H, NH). 13C NMR (125.75 MHz, DMSO-d6): δ 13.8 (CH3,
Meacac), 14.9 (CH3, Meacac), 26.1 (2C, CH3, Meacac), 26.5 (2C,
CH3, Meacac), 41.8 (CH2, en), 50.9 (CH2, en), 98.3 (Cq, Meacac),
100.5 (Cq, Meacac), 113.4 (CH, quin)*, 121.2 (Cq, ph), 121.3 (CH,
ph), 124.7 (CH, ph), 126.5 (2C, CH, quin + ph), 130.0 (CH, quin)*,
130.6 (CH, ph), 140.6 (Cq, ph), 142.8 (Cq, quin), 153.7 (CH, quin)*,
157.0 (Cq, quin), 186.2 (Cq, acac), 186.9 (Cq, acac), 187.3 (Cq, acac),
187.9 (Cq, acac).
Shifts of the minor isomer. 1HNMR (500.1MHz, DMSO-d6): δ 1.77
(s, 3H, CH3, Meacac), 1.78 (s, 3H, CH3, Meacac), 1.99 (s, 3H, CH3,
Meacac), 2.05−2.06 (m, 3H, CH3, Meacac), 2.20 (s, 3H, CH3,
Meacac), 2.34 (s, 3H, CH3, Meacac), 2.67−2.97 (m, 3H, en), 3.72−
3.80 (m, 1H, en), 5.28−5.37 [m, 1H, NH2(en)], 5.73−5.80 [m, 1H,
NH2(en)], 7.18 (dd, 1H, J = 9 Hz, J = 2 Hz, quin), 7.36−7.43 (m, 2H,
ph), 7.46 [m, 1H, NH(en)], 7.71 (d, 1H, J = 9Hz, quin), 7.82−7.89 (m,
1H, ph), 8.14−8.17 (m, 1H, ph), 8.65−8.70 (m, 2H, quin), 10.25 (s,
1H, NH). 13C NMR (125.75 MHz, DMSO-d6): δ 14.7 (CH3, Meacac),
14.9 (CH3, Meacac)*, 25.9 (CH3, Meacac), 26.6 (CH3, Meacac), 26.8
(CH3, Meacac), 26.7 (CH3, Meacac), 51.2 (CH2, en)*, 52.2 (CH2,
en)*, 100.4 (Cq, Meacac), 100.6 (Cq, Meacac), 114 (2C, CH, quin)*,
121.3 (CH, ph)*, 124.7 (CH, ph)*, 126.5 (2C, CH, -quin + ph)*,
129.3 (CH, quin)*, 130.6 (CH, ph)*, 153.7 (CH, quin)*, 187.7 (Cq,
Meacac), 188.2 (Cq, Meacac).
MS: calcd for [C28H34BrCoN5O4]
+, 642.11; found, 642.28. Anal.
Calcd for C28H34BrClCoN5O4·2H2O (Mr = 714.92 g/mol): C, 47.04;
H, 5.36; N, 9.80. Found: C, 46.85; H, 5.09; N, 9.68. *Detected only in
two-dimensional (2D) NMR.
Bis(2 ,4-pentanedionato) N4-(3-Bromophenyl ) -N6- [2-
(methylamino)ethyl]quinazoline-4,6-diamine Cobalt(III) Chloride
[Co(acac)2MeL
+]. Na[Co(acac)2(NO2)2] (83.6 mg, 0.23 mmol) was
dissolved in H2O (1.6 mL) and MeOH (1.6 mL).MeL (105 mg, 0.24
mmol) was dissolved in H2O (1.1 mL), neutralized with NaOH (1.9
mL, 0.25 M in MeOH), and subsequently added to the cobalt complex
solution with activated charcoal (55.2 mg). The resulting mixture was
stirred for 1 h at room temperature, filtered through Celite, and washed
with small amounts of MeOH. Brine (6.1 mL) was added to the filtrate,
and the resulting solution was extracted with dichloromethane (3 × 10
mL). The organic phase was separated, dried with Na2SO4, and
evaporated. The crude product (115 mg of a dark green solid) was
purified by RP-HPLC (H2O/ACN, 30−42% ACN, 26 min, without
formic acid or TFA to avoid counter ion exchange). Yield: 63 mg
(40%). The ratio of the four isomers (A:B:C:D) was 1:0.42:0.33:0.20.
Shifts of the main isomer A. 1H NMR (500.1 MHz, DMSO-d6): δ
1.56 (s, 3H, CH3, acac), 1.77 (d, 3H, J = 6Hz, CH3,MeEn), 2.01 (s, 3H,
CH3, acac), 2.02 (s, 3H, CH3, acac), 2.30 (s, 3H, CH3, acac), 2.58−3.04
(m, 3H, CH2, MeEn), 3.68−3.92 (m, 1H, CH2, MeEn), 4.79 (s, 1H,
CH, acac), 5.67−5.75 (m, 1H, CH, acac), 6.74 [m, 1H, NH(en)],
7.33−7.43 (m, 2H, CH, ph), 7.46 (dd, 1H, CH, J = 8 Hz, J = 2 Hz,
quin), 7.61−7.73 (m, 1H, CH, quin), 7.83−7.94 (m, 1H, CH, ph), 8.13
(t, 1H, CH, ph), 8.23−8.27 (m, 1H, CH, quin), 8.29−8.38 [m, 1H,
NH(en)], 8.62−8.70 (m, 1H, CH, quin), 10.13 (s, 1H, NH). 13C NMR
(125.75 MHz, DMSO-d6): δ 26.2 (CH3, acac), 26.4 (CH3, acac), 26.5
(CH3, acac), 26.6 (CH3, acac), 37.5 (CH3, MeEn), 50.8 (CH2, MeEn),
53.1 (CH2, MeEn), 96.4 (CH, acac), 98.8 (CH, acac), 115.7 (Cq,
quin)*, 121.6 (Cq, ph), 121.8 (CH, ph), 125.3 (CH, ph), 127.0 (CH,
ph), 127.5 (CH, quin), 130.9 (CH, quin), 131.0 (CH, ph), 141.1 (Cq,
ph), 142.7 (Cq, quin), 148.5 (Cq, quin)*, 157.5 (Cq, quin), 189.6 (Cq,
acac), 189.7 (Cq, acac), 190.0 (Cq, acac), 190.9 (Cq, acac).
Shifts of isomer B. 1H NMR (500.1 MHz, DMSO-d6): δ 1.68 (s, 3H,
CH3, acac), 2.06 (d, 3H, J = 6Hz, CH3,MeEn), 2.03 (s, 3H, CH3, acac),
2.11 (s, 3H, CH3, acac), 2.26 (s, 3H, CH3, acac), 2.58−3.04 (m, 3H,
CH2, MeEn), 3.68−3.92 (m, 1H, CH2, MeEn), 5.55 (s, 1H, CH, acac),
5.67−5.75 (m, 1H, CH, acac), 6.18 [m, 1H, NH(en)], 7.29 (dd, 1H,
CH, J = 8 Hz, J = 2 Hz, quin), 7.33−7.43 (m, 2H, CH, ph), 7.61−7.73
(m, 1H, CH, quin), 7.83−7.94 [m, 2H, CH, ph + NH(en)], 8.16 (m,
1H, CH, ph), 8.62−8.70 (m, 1H, CH, quin), 8.70−8.74 (m, 1H, CH,
quin), 10.23 (s, 1H, NH). 13C NMR (125.75 MHz, DMSO-d6): δ 26.5
(CH3, acac), 26.8 (CH3, acac), 26.9 (CH3, acac), 27.0 (CH3, acac),
35.8 (CH3, MeEn), 49.8 (CH2, MeEn), 53.5 (CH2, MeEn), 98.3 (2C,
CH, acac), 115.7 (CQ, quin)*, 116.1 (CH, quin)*, 121.6 (Cq, ph),
121.7 (CH, ph), 125.2 (CH, ph), 126.9 (CH, ph), 127.5 (CH, quin),
129.6 (CH, quin), 131.0 (CH, ph), 141.3 (Cq, ph), 142.5 (Cq, quin),
148.5 (Cq, quin)*, 157.8 (Cq, quin), 189.0 (Cq, acac), 189.7 (Cq, acac),
189.8 (Cq, acac), 190.1 (Cq, acac).
Shifts of isomer C. 1H NMR (500.1 MHz, DMSO-d6): δ 1.76 (s, 3H,
CH3, acac), 1.90 (d, 3H, J = 6Hz, CH3,MeEn), 1.99 (s, 3H, CH3, acac),
2.07 (s, 3H, CH3, acac), 2.26 (s, 3H, CH3, acac), 2.58−3.04 (m, 3H,
CH2, MeEn), 4.16−4.27 (m, 1H, CH2, MeEn), 5.51 (s, 1H, CH, acac),
5.67−5.75 (m, 1H, CH, acac), 6.87 [m, 1H, NH(en)], 7.25 (dd, 1H,
CH, J = 8 Hz, J = 2 Hz, quin), 7.33−7.43 (m, 2H, CH, ph), 7.61−7.73
(m, 1H, CH, quin), 7.83−7.94 [m, 1H, NH(en)], 7.98 (d, 1H, J = 9.0
Hz, CH, ph), 8.16 (m, 1H, CH, ph), 8.62−8.70 (m, 1H, CH, quin),
8.98 (s, 1H, CH, quin), 10.33 (s, 1H, NH). 13C NMR (125.75 MHz,
DMSO-d6): δ 26.5 (CH3, acac)*, 26.7 (CH3, acac)*, 27.0 (CH3,
acac)*, 27.1 (CH3, acac)*, 36.6 (CH3, MeEn)*, 52.9 (CH2, MeEn)*,
51.1 (CH2, MeEn)*, 98.1 (CH, acac), 114.4 (CH, quin)*, 115.7 (Cq,
quin)*, 117.0 (CH, quin)*, 121.6 (Cq, ph)*, 122.0 (CH, ph), 125.6
(CH, ph), 127.0 (CH, ph)*, 127.5 (CH, quin), 129.6 (CH, quin),
131.0 (CH, ph), 141.3 (Cq, ph), 142.1 (Cq, quin)*, 148.5 (Cq, quin)*,
189.6 (Cq, acac), 190.1 (Cq, acac), 190.4 (Cq, acac).
Shifts of isomer D. 1H NMR (500.1 MHz, DMSO-d6): δ 1.71 (s, 3H,
CH3, acac), 1.88 (s, 3H, CH3, acac), 2.19 (d, 3H, J = 6 Hz, CH3,
-MeEn), 2.58−3.04 (m, 3H, CH2, MeEn), 3.68−3.92 (m, 1H, CH2,
MeEn), 4.75 (s, 1H, CH, acac), 5.67−5.75 (m, 1H, CH, acac), 6.18 [m,
1H, NH(en)], 7.33−7.43 (m, 2H, CH, ph), 7.61−7.73 (m, 1H, CH,
quin), 7.83−7.94 (m, 1H, CH, ph), 8.23−8.27 (m, 1H, CH, ph), 8.29−
8.38 [m, 1H, NH(en)], 8.62−8.70 (m, 1H, CH, quin), 8.70−8.74 (m,
1H, CH, quin), 10.21 (s, 1H, NH). 13C NMR (125.75 MHz, DMSO-
d6): δ 26.5 (CH3, acac)*, 26.7 (CH3, acac)*, 35.4 (CH3, MeEn), 53.5
(CH2, MeEn)*, 96.5 (CH, acac)*, 98.6 (CH, acac)*, 115.7 (Cq,
quin)*, 121.6 (Cq, ph)*, 122.1 (CH, ph), 125.4 (CH, ph), 127.0 (CH,
ph)*, 127.5 (CH, quin), 143.4 (Cq, quin)*, 189.3 (Cq, acac)*, 189.5
(Cq, acac)*, 131.0 (CH, ph).
MS: calcd for [C27H32BrCoN5O4]
+, 628.10; found, 628.26. Anal.
Calcd for C27H32BrClCoN5O4·2H2O (Mr = 700.89 g/mol): C, 46.27;
H, 5.18; N, 9.99. Found: C, 46.24; H, 5.05; N, 9.77. *Detected only in
2D NMR.
Bis(3-methyl-2,4-pentanedionato) N4-(3-Bromophenyl)-N6-[2-
(methylamino)ethyl]quinazoline-4,6-diamine Cobalt(III) Chloride
[Co(Meacac)2MeL
+]. Na[Co(Meacac)2(NO2)2] (85.6 mg, 0.21
mmol) was dissolved in H2O (1.6 mL) and MeOH (1.2 mL). MeL
(100 mg, 0.23 mmol) was dissolved in H2O (1 mL), neutralized with
NaOH (1.8 mL, 0.25 M in MeOH), and then added with activated
charcoal (52.5 mg) to the cobalt precursor solution. The resulting
mixture was stirred for 1 h at room temperature and filtered through
Celite, which was washed with small amounts of MeOH. Brine
(5.8 mL) was added to the filtrate, and the resulting solution was
extracted with dichloromethane (3 × 10 mL). The organic phase was
separated, dried with Na2SO4, and evaporated. The crude product (100
mg of a dark green solid) was purified by RP-HPLC (H2O/ACN, 30−
42% ACN, 26 min, without formic acid or TFA to avoid counter ion
exchange). Yield: 37.6 mg (24%). The ratio of the four isomers
(A:B:C:D) was 1:0.34:0.23:0.19.
Shifts of the main isomer A. 1H NMR (500.1 MHz, DMSO-d6): δ
1.00 (s, 3H, CH3, Meacac), 1.57 (s, 3H, CH3, Meacac), 1.67−1.72 (m,
3H, CH3, MeEn), 1.90 (s, 3H, CH3, Meacac), 2.08 (s, 3H, CH3,
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Meacac), 2.11 (s, 3H, CH3,Meacac), 2.41 (s, 3H, CH3,Meacac), 2.58−
3.00 (m, 3H, CH2, MeEn), 3.60−3.83 (m, 1H, CH2, MeEn), 6.61−6.76
[m, 1H, NH(en)], 7.31−7.44 (m, 2H, CH, ph), 7.48 (d, 1H, CH, J = 9
Hz, -quin), 7.55−7.71 (m, 1H, CH, -quin), 7.84 (d, 1H, J = 2.0 Hz, CH,
ph), 8.06−8.17 [m, 3H, CH, quin + ph + NH(en)], 8.60−8.72 (m, 1H,
quin), 10.09 (s, 1H, NH). 13C NMR (125.75 MHz, DMSO-d6): δ 13.8
(CH3, Meacac)*, 14.7 (CH3, Meacac), 26.1 (CH3, Meacac), 26.3
(CH3, Meacac), 26.4 (CH3, Meacac), 26.6 (CH3, Meacac), 36.9 (CH3,
MeEn), 50.2 (CH2, MeEn), 53.0 (CH2, MeEn), 98.5 (Cq, Meacac),
101.2 (Cq, Meacac), 113.7 (CH, quin)*, 121.1 (CH, ph), 124.6 (CH,
ph), 126.4 (CH, ph), 127.1 (CH, quin)*, 130.1 (CH, quin)*, 130.6
(CH, ph), 140.9 (Cq, ph), 142.5 (Cq, quin), 156.9 (Cq, quin), 187.0
(Cq, Meacac), 187.4 (Cq, Meacac), 187.5 (CCq, Meacac), 188.2 (Cq,
Meacac).
Shifts of isomer B. 1H NMR (500.1 MHz, DMSO-d6): δ 1.67−1.72
(m, 3H, CH3, Meacac), 1.79 (s, 3H, CH3, Meacac), 1.95 (s, 3H, CH3,
Meacac), 2.04−2.14 (m, 6H, CH3, acac + MeEn), 2.23 (s, 3H, CH3,
Meacac), 2.33 (s, 3H, CH3, Meacac), 2.58−3.00 (m, 3H, CH2, MeEn),
3.60−3.83 (m, 1H, CH2, MeEn), 5.85 [m, 1H, NH(en)], 7.13−7.23
(m, 1H, CH, quin), 7.31−7.44 (m, 2H, CH, ph), 7.55−7.71 (m, 1H,
CH, -quin), 7.87−8.03 [m, 2H, CH, ph + NH(en)], 8.24 (s, 1H, CH,
ph), 8.60−8.72 (m, 1H, CH, quin), 8.75 (s, 1H, CH, quin), 10.23 (s,
1H, NH). 13C NMR (125.75 MHz, DMSO-d6): δ 14.6 (CH3, Meacac),
14.7 (CH3, Meacac), 35.2 (CH3, MeEn), 26.4 (CH3, Meacac), 26.6
(CH3, Meacac)*, 26.9 (CH3, Meacac), 26.1 (CH3, Meacac), 52.5
(CH2, MeEn), 100.7 (2C, Cq, Meacac), 121.1 (CH, ph), 124.6 (CH,
ph)*, 126.4 (CH, ph), 127.1 (CH, quin)*, 129.2 (CH, quin), 130.6
(CH, ph), 187.0 (Cq, Meacac), 187.3 (Cq, Meacac), 188.0 (Cq,
Meacac).
Shifts of isomer C. 1H NMR (500.1 MHz, DMSO-d6): δ 1.75 (s, 3H,
CH3, Meacac), 1.77−1.83 (m, 3H, CH3, MeEn), 1.82 (s, 3H, CH3,
Meacac), 1.97 (s, 3H, CH3, Meacac), 2.04−2.14 (m, 3H, CH3,
Meacac), 2.19 (s, 3H, CH3,Meacac), 2.37 (s, 3H, CH3,Meacac), 2.58−
3.00 (m, 3H, CH2, MeEn), 3.60−3.83 (m, 1H, CH2, MeEn), 6.61−6.76
[m, 1H, NH(en)], 7.13−7.23 (m, 1H, CH, quin), 7.31−7.44 (m, 2H,
CH, ph), 7.55−7.71 (m, 1H, CH, quin), 7.87−8.03 [m, 2H, CH, ph +
NH(en)], 8.19 (s, 1H, CH, ph), 8.60−8.72 (m, 1H, CH, quin), 8.90 (s,
1H, CH, -quin), 10.28 (s, 1H, NH). 13C NMR (125.75 MHz, DMSO-
d6): δ 14.6 (CH3, Meacac), 14.7 (CH3, Meacac), 34.9 (CH3, MeEn),
26.2 (CH3, Meacac), 26.4 (CH3, Meacac)*, 52.7 (CH2, MeEn)*, 100.7
(2C, Cq, Meacac), 121.1 (CH, ph), 124.6 (CH, ph)*, 126.4 (CH, ph)*,
127.1 (CH, quin)*, 129.3 (CH, quin), 130.6 (CH, ph), 187.2 (Cq,
Meacac)*, 187.5 (C, Cq, Meacac)*.
Shifts of isomer D. 1H NMR (500.1 MHz, DMSO-d6): δ 1.76 (s, 3H,
CH3, MeEn), 1.77−1.83 (m, 3H, CH3, Meacac), 1.99 (s, 3H, CH3,
Meacac), 2.04−2.14 (m, 3H, CH3, Meacac), 2.21−2.26 (m, 3H, CH3,
MeEn), 2.33 (s, 3H, CH3, Meacac), 2.58−3.00 (m, 3H, CH2, MeEn),
3.60−3.83 (m, 1H, CH2, MeEn), 5.85 [m, 1H, NH(en)], 7.31−7.44
(m, 2H, CH, ph), 7.47 (m, 1H, CH, quin), 7.55−7.71 (m, 1H, CH,
quin), 8.24 (s, 1H, CH, ph), 8.06−8.17 [m, 3H, CH, quin + ph +
NH(en)], 8.60−8.72 (m, 1H, CH, quin), 10.14 (s, 1H, NH). 13C NMR
(125.75 MHz, DMSO-d6): δ 14.6 (CH3, Meacac)*, 14.8 (CH3,
Meacac)*, 36.0 (CH3,MeEn)*, 26.4 (CH3,Meacac)*, 121.1 (CH, ph),
124.6 (CH, ph)*, 126.4 (CH, ph)*, 127.1 (CH, quin)*, 130.1 (CH,
quin)*, 130.6 (CH, ph), 186.4 (Cq, acac)*, 187.7 (Cq, Meacac)*, 188.3
(Cq, Meacac)*.
MS: calcd for [C29H36BrCoN5O4]
+, 656.13; found, 656.13. Anal.
Calcd for C29H36BrClCoN5O4·2H2O (Mr = 728.95 g/mol): C, 47.78;
H, 5.53; N, 9.61. Found: C, 47.58; H, 5.40; N, 9.64. *Detected only in
2D NMR.
Bis(2,4-pentanedionato) (Phenyl-1,2-ethylenediamine) Cobalt-
(III) Hexafluorophosphate [Co(acac)2PhEn
+].Na[Co(acac)2(NO2)2]
(100 mg, 0.27 mmol) was dissolved in H2O (1.5 mL) and MeOH (1
mL), and N-phenylethylenediamine (36.9 μL, 0.28 mmol) was added
to the solution with a spatula tip of activated charcoal. The reaction
mixture was stirred for 1 h at room temperature and filtered through
Celite. NH4PF6 (152.4 mg, 0.94 mmol) was added to the filtrate, and
the solution was stored at 4 °C overnight. The formed grayish violet
solid was filtered off and washed with ice-cold H2O and Et2O. Yield: 45
mg (30%). The ratio of the two isomers was 1:0.81.
Shifts of the main isomer. 1H NMR (500.1 MHz, DMSO-d6): δ 1.69
(s, 3H, CH3, acac), 2.00 (s, 3H, CH3, acac), 2.10 (s, 3H, -CH3, acac),
2.18 (s, 3H, CH3, acac), 2.52−2.91 (m, 3H, CH2, phEn), 3.19−3.25 (m,
1H, CH2, phEn), 5.35 (s, 1H,NH2), 5.56 (s, 1H, CH, acac), 5.66 (s, 1H,
CH, acac), 5.88 (s, 1H, NH2), 7.01 (d, 1H, J = 2 Hz, CH, ph), 7.15 (d,
2H, J = 3 Hz, NH), 7.19−7.35 (m, 8H, CH, ph).
Shifts of theminor isomer. 1HNMR (500.1MHz, DMSO-d6): δ 1.70
(s, 3H, CH3, acac), 1.95 (s, 3H, -CH3, acac), 1.98 (s, 3H, CH3, acac),
2.19 (s, 3H, CH3, acac), 2.52−2.91 (m, 3H, CH2, phEn), 3.19−3.25 (m,
1H, CH2, phEn), 4.91 (s, 1H, CH, acac), 5.54 (s, 1H,NH2), 5.64 (s, 1H,
CH, acac), 5.64 (s, 1H, NH2), 7.01 (d, 1H, J = 2 Hz, CH, ph), 7.19−
7.35 (m, 4H, CH, ph), 7.76 (d, 2H, J = 3 Hz, NH).
MS: calcd for [C18H26CoN2O4]
+, 393.12; found, 393.04. Anal. Calcd
for C18H26CoF6N2O4P·0.5H2O (Mr = 547.32 g/mol): C, 39.50; H,
4.97; N, 5.12. Found: C, 39.75; H, 4.82; N, 4.96.
Bis(3-methyl-2,4-pentanedionato) Ethylenediamine Cobalt(III)
Hexafluorophosphate [Co(Meacac)2en
+].Na[Co(Meacac)2(NO2)2]
(150 mg, 0.37 mmol) was dissolved in H2O (2.25 mL) andMeOH (1.5
mL), and ethylenediamine (26.3 μL, 0.39 mmol) was added with a
spatula tip of activated charcoal. The reactionmixture was stirred for 1.5
h at room temperature and filtered through a syringe filter. NH4PF6
(212 mg, 1.3 mmol) was added to the filtrate, and the solution was
stored at room temperature for 2 h. Violet and orange crystals
precipitated after a while. The solid was filtered off and washed with ice-
cold H2O and Et2O. Separation of the two compounds was carried out
by dissolution inMeOH. The insoluble orange crystals were filtered off,
and the violet filtrate was evaporated and dried in vacuo. Yield: 30 mg
(16%). 1H NMR (500.1 MHz, DMSO-d6): δ 1.86 (s, 6H, CH3,
Meacac), 2.13 (s, 6H, CH3, Meacac), 2.15 (s, 6H, CH3, Meacac), 2.34
(m, 2H, CH2, en), 2.45 (m, 2H, CH2, en), 4.78 (s, 2H, NH2), 5.21 (s,
2H, NH2). MS: calcd for [C18H26CoN2O4]
+, 345.12; found, 345.10.
Anal. Calcd for C14H26CoF6N2O4P·0.5H2O (Mr = 499.27 g/mol): C,
33.68; H, 5.45; N, 5.61. Found: C, 33.85; H, 5.70; N, 5.39.
Bis(2,4-pentanedionato) (Methyl-1,2-ethanediamine) Cobalt(III)
Hexafluorophosphate [Co(acac)2MeEn
+]. Na[Co(acac)2(NO2)2]
(500 mg, 1.34 mmol) was dissolved in H2O (7.5 mL) and MeOH (5
mL), andN-methylethylenediamine (123 μL, 1.41 mmol) was added to
the solution with a spatula tip of activated charcoal. The reaction
mixture was stirred for 1.5 h at room temperature and filtered through
Celite. NH4PF6 (763 mg, 4.68 mmol) was added to the filtrate, and the
solution was stored at 4 °C for 4 days. The formed violet crystals were
filtered off and washed with ice-cold H2O and Et2O. Yield: 252 mg
(39%). 1H NMR (500.1 MHz, DMSO-d6): δ 1.67 (d, 3H, J = 9 Hz,
CH3, MeEn), 2.04 (s, 3H, CH3, acac), 2.06 (s, 3H, CH3, acac), 2.09 (s,
6H, CH3, acac), 2.34−2.6 (m, 4H, CH2, MeEn), 5.27 (m, 2H, NH2),
5.61 (s, 1H, CH, acac), 5.63 (s, 1H, CH, acac), 6.16 (s, 1H, NH). MS:
calcd for [C13H24CoN2O4]
+, 331.11; found, 331.10. Anal. Calcd for
C13H24CoF6N2O4P (Mr = 476.24 g/mol): C, 32.79; H, 5.08; N, 5.88.
Found: C, 32.57; H, 5.11; N, 5.83.
Bis(3-methyl-2,4-pentanedionato) (Methyl-1,2-ethanediamine)
Cobalt(III) Hexafluorophosphate [Co(Meacac)2MeEn
+]. Na[Co-
(Meacac)2(NO2)2] (100 mg, 0.25 mmol) was dissolved in H2O (1.5
mL) and MeOH (1 mL), and N-methylethylenediamine (22.9 μL,
0.26 mmol) was added with a spatula tip of activated charcoal. The
reaction mixture was stirred for 1.5 h at room temperature and filtered
through a syringe filter. NH4PF6 (142mg, 0.87 mmol) was added to the
filtrate, and the solution was stored at room temperature for 2 h. The
precipitated purple crystals were filtered off and washed with ice-cold
H2O and Et2O. Yield: 20 mg (16%). The ratio of the two isomers was
1:0.30.
Shifts of the main isomer. 1H NMR (500.1 MHz, DMSO-d6): δ 1.60
(d, 3H, J = 8 Hz, CH3, MeEn), 1.84 (s, 3H, CH3, Meacac), 1.88 (s, 3H,
CH3, Meacac), 2.11 (s, 3H, CH3, Meacac), 2.16 (s, 3H, CH3, Meacac),
2.18 (s, 3H, CH3, Meacac), 2.21 (s, 3H, CH3, Meacac), 2.23−2.40 (m,
3H, CH2, MeEn), 2.62 (s, 1H, CH2, MeEn), 4.97 (s, 1H, NH2), 5.13 (s,
1H, NH2), 5.96 (s, 1H, NH).
Shifts of theminor isomer. 1HNMR (500.1MHz, DMSO-d6): δ 1.86
(s, 3H, CH3,MeEn), 1.89 (s, 3H, CH3,Meacac), 1.95 (d, 3H, J = 11Hz,
CH3, Meacac), 2.14 (s, 6H, CH3, Meacac), 2.16 (s, 3H, CH3, Meacac),
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2.21 (s, 3H, CH3, Meacac), 2.23−2.40 (m, 3H, CH2, MeEn), 2.62 (s,
1H, CH2, MeEn), 4.81 (s, 1H, NH), 5.35 (m, 2H, NH2).
MS: calcd for [C15H28CoN2O4]
+, 359.14; found, 359.12. Anal. Calcd
for C15H28CoF6N2O4P·0.5H2O (Mr = 522.31 g/mol): C, 35.1; H, 5.69;
N, 5.46. Found: C, 35.21; H, 5.64; N, 5.16.
Kinase Screening. The EGFR (ErbB1) kinase-inhibitory potential
of the novel ligandMeL in comparison to that of previously synthesized
ligand L was evaluated using the Select Screen Biochemical Kinase
Profiling Service at Life Technologies (ThermoFisher Scientific,
Madison, WI). The test compounds were screened in a final DMSO
concentration of 1% using the ZLYTE Assay in the presence of 10 μM
ATP.
Fluorescence Measurements. Fluorescence measurements were
performed on a Horiba FluoroMax-4 spectrofluorometer, and the data
were analyzed using FluorEssence version 3.5. The tested solutions
were dissolved immediately prior to analysis in PBS (10 mM, pH 7.4)
with a final concentration of 3 × 10−5 M. Scans were run at room
temperature with excitation and emission slit widths of 4 nm. Emission
scans were run from 375 to 600 nm using an excitation wavelength of
365 nm. The 3D fluorescence spectra of L andMeLwere determined at
excitation wavelengths from 220 to 550 nm, and emission was recorded
within the range of 200−600 nm.
Lipophilicity. Distribution coefficient (D7.4) values of the studied
cobalt(III) compounds were determined by the traditional shake-flask
method in an n-octanol/buffered aqueous solution at pH 7.40 (PBS)
and 25.0 ± 0.2 °C as described previously.51 The complexes were
dissolved in an n-octanol presaturated aqueous solution of the buffer at
∼100 μM. After phase separation, the UV−vis spectrum of the
compound in the aqueous phase was compared to that of the original
stock solution and the D7.4 values of the compounds were calculated
according to the following formula: [absorbance(original solution)/
absorbance(aqueous phase after separation) − 1].
Chemicals for Analytical Measurements. All solvents were of
analytical grade and used without further purification. MeEn, PhEn,
acac, Meacac, KH-phthalate, K3[Fe(III)(CN)6], KCl, NaCl, HCl,
KOH, AA, GSH, and reduced NADH were products of Sigma-Aldrich.
CoCl2·H2O, NaH2PO4, and Na2HPO4 were purchased from Reanal,
and the exact concentration of the CoCl2 stock solution was determined
by complexometry via its EDTA complex. Milli-Q water was used for
sample preparation.
Cyclic Voltammetry. The compounds were dissolved in 10 mM
phosphate buffer (pH 7.40), with 0.1 M KCl as the supporting
electrolyte, to obtain a final concentration of 1.5 mM. Electrochemical
experiments were conducted on an EG&G PARC 273A potentiostat/
galvanostat with scan rates of 30 and 1000 mV/s at room temperature.
Argon was bubbled through the solution before every measurement to
remove oxygen. A three-electrode configuration cell was used with a
glassy carbon electrode as the working electrode, which was polished
before every measurement. The reference electrode was Ag/AgCl/KCl
(3.5 M), and the auxiliary electrode was a platinum wire. Electrodes
were conditioned regularly in 1 M H2SO4 for 5−10 cycles between
voltage limits of −1.0 and 1.0 V at a scan rate of 100 mV/s. The system
was calibrated with 1.5 mM K3[Fe(CN)6] for every experiment. Redox
potentials measured relative to the Ag/AgCl/KCl (3.5 M) reference
electrode were converted for potentials against NHE by the addition of
0.205 V. Measurements were repeated at least three times, and the
mean values were calculated.
Spectroscopic Studies of the Proton Dissociation and Redox
Processes. Proton dissociation processes of PhEn were followed by
UV−vis spectrophotometry and spectrofluorometry; samples were
prepared in water containing 100 and 10 μM ligand, respectively, and
0.1 M KCl at 25 ± 0.2 °C. The proton dissociation constants and the
UV−vis or fluorescence emission spectra of the individual species in the
various protonation states were calculated by deconvolution of the
spectra recorded in the pH range of 2.0−11.5 with PSEQUAD.40
Reduction of the cobalt(III) compounds by AA, GSH, and NADH in
aqueous solutions was followed for 24 h at 25.0 °C. All solutions were
prepared under strictly oxygen-free conditions in an argon atmosphere.
Batch samples contained 30 μM cobalt(III) complex and 10 equiv of
AA, GSH, or NADH in PBS buffer (pH 7.40) and were used only once
to record their UV−vis and fluorescence spectra. A Hewlett Packard
8452A diode array spectrophotometer was used in the interval of 200−
800 nm, and aHitachi F-4500 spectrofluorometer was applied to record
the emission spectra (λEX = 290 nm and λEM = 310−450 nm in case of
the titration of PhEn; λEX = 370 nm and λEM = 400−600 nm in the case
of redox reactions).
pH-Potentiometric Measurements and Data Evaluation. For
determination of the proton dissociation (Ka) and formation constants
(β) pH-potentiometric measurements were carried out at 25 ± 0.1 °C
and an ionic strength (I) of 0.10 M (KCl) to keep the activity
coefficients constant. A carbonate-free KOH solution (0.10 M) was
used for titrations. The exact concentrations of HCl and KOH were
determined by pH-potentiometric titrations. A Metrohm-combined
electrode (type 6.0234.100) connected to an Orion 710A pH-meter
and a computer-controlled Methrom 665 Dosimat buret (increment, 1
μL; precision, 2 μL) were used for the pH-potentiometric measure-
ments. The electrode system was calibrated to the pH =−log[H+] scale
by means of blank titrations (strong acid HCl vs strong base KOH), as
suggested by Irving et al.52 The determined average water ionization
constant (pKw = 13.76± 0.01) corresponds well to the literature data.
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Titration points included in the calculations gave a reproducibility
within 0.005 pH unit. Titrations were performed in the pH range of
2.0−11.5, and the initial volume of the samples was 10 mL. Binary
systems contained 1 or 2 mM ligand, and metal:ligand ratios of 1:1, 1:2,
1:3, and 1:4 were used. In the ternary systems, the cobalt(II)
concentration was 1 mM and the two types of ligands (A, acac, and
B, MeEn, or PhEn) were varied as follows: 1:1:1, 1:2:1, 1:1:2, and 1:2:2
Co(II):A:B. The samples were degassed by bubbling purified argon
through them for 10 min prior to the measurements, and argon was also
passed over the solutions during the titrations.
The stoichiometry of the complexes and overall stability constants
were established by the computer program Hyperquad2013.53 For the
general equilibrium β(MpLqHr) is defined as
β+ + = [ ] [ ] [ ] [ ]p q rM L H M L H as (M L H ) M L H / M L Hp q r p q r p q r
p q rF
(1)
where M denotes the cobalt(II) ion and L the completely deprotonated
ligand. The calculations were performed as reported in our previous
work.54
Serum Stability Measurements. For serum stability measure-
ments, 135 μL of FCS, buffered with 150 mM phosphate (Na2HPO4/
NaH2PO4) to maintain a pH value of 7.4, was mixed with 15 μL of a 500
μMstock solution of the respective complex in 50mMphosphate buffer
to reach a final concentration of 50 μM. The samples were incubated at
37 °C. At different time points, to 20 μL of serum was added 40 μL of
ACN. After being vigorously shaked for 2 min, the suspension was
centrifuged at 6000 rpm for 10 min. The supernatant was taken up with
a syringe and directly measured via HPLC-MS.
Biological Methods. Chemicals for Cell Culture Tests. All
investigated drugs were dissolved in DMSO. These stock solutions
(10 mM) were further diluted into culture media containing 10% FCS
at the indicated concentrations. The final DMSO concentrations were
always less than 1%. All other substances were purchased from Sigma-
Aldrich (St. Louis, MO).
Cell Culture. Human cancer cell line A431 (epidermoid carcinoma,
overexpressing EGFR/wt) was purchased fromAmerican Type Culture
Collection (ATCC) (Rockville, MD). The cell line was grown, unless
otherwise indicated, in humidified incubators (37 °C, 21% O2, and 5%
CO2) in RPMI 1640 containing 10% FCS (PAA, Linz, Austria). Under
hypoxic conditions, plated and treated cells were incubated in
humidified incubators (ProOx model C21 system von BioSpherix)
with 0.1%, 1%, or 5% CO2 for the indicated period of time before
analysis.
Cytotoxicity Assay. A431 cells were seeded (3 × 103 cells/well) in
96-well plates, and after recovery for 24 h, the dissolved drugs were
added in increasing concentrations. After exposure to the drug for 72 h,
the proportion of viable cells was determined by the MTT assay
following the manufacturer’s recommendations (EZ4U, Biomedica,
Vienna, Austria). Cytotoxicity was expressed as IC50 values calculated
from full dose−response curves using GraphPad Prism.
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Western Blot Analysis. A431 cells were plated (1 × 106 cells/60 mm
dish) and allowed to recover for 24 h, followed by serum starvation for
24 h (except the nonstarving control). Subsequently, the cells were
treated with the drugs in different concentrations for 2 h. In the final 10
min, EGF was added with a final concentration of 50 ng/mL to
stimulate EGFR. Then, cells were harvested, and proteins were isolated,
resolved by sodium dodecyl sulfate−polyacrylamide gel electro-
phoresis, and transferred onto a polyvinylidene difluoride membrane
for Western blotting as previously described.17 The following
antibodies were used: EGFR (8198), p-EGFR (Tyr1068) (3077),
ERK 1/2 (9102), and p-ERK 1/2 (Thr202/Tyr204) (9101) (all
monoclonal rabbit, Cell Signaling Technology, Beverly, MA) and β-
actin (monoclonal mouse, Sigma). All primary antibodies were used in
1:1000 dilutions [in Tris-buffered saline containing 0.1% Triton X-100
(TBST) with 3% bovine serum albumin (BSA)]. Additionally,
horseradish peroxidase-labeled anti-mouse (7076) and anti-rabbit
(7074) secondary antibodies were used at working dilutions of 1:10000
(in TBST with 1% BSA).
Fluorescence Microscopy. A431 cells were seeded (5 × 105 cells/
well) in six-well plates and allowed to recover overnight. Then, cells
were treated with 10 μM investigated drugs (diluted with 10% FCS-
containing medium) for 6 or 24 h. After incubation, the drug solutions
were removed, and the cells were washed with PBS. Subsequently,
microphotographs were taken using UV fluorescence microscopy
(Nikon Eclipse Ti microscope with a DAPI filter and a high-pressure
mercury lamp) and a 10× objective.
Flow Cytometry. For better quantification of the fluorescence
intensity of released EGFR inhibitors, the previously microscoped cells
were trypsinized, harvested, and centrifuged. The pellets were washed
twice with PBS and further resuspended in Dulbecco’s modified Eagle’s
medium (DMEM). Subsequently, the samples were measured on a LSR
Fortessa flow cytometer (BD Biosciences, East Rutherford, NJ). The
compound fluorescence was detected using 405 nm excitation and
Pacific Blue (450/50 nm) band pass emission filters. Data were
analyzed using the FACSDiva software and are depicted as the percent
of fluorescence-positive cells and as the fluorescence intensity
normalized to the autofluorescence.
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